Latest Conference Articles

The availability of several new treatments has dramatically transformed the treatment paradigm for multiple myeloma in the past few years.

Alessandro Gronchi, MD, discusses the impact of olaratumab and other emerging agents for the treatment of sarcoma, as well as what to expect at this year’s CTOS meeting.

Alessandro Gronchi, MD, president, Connective Tissue Oncology Society (CTOS), discusses some of the exciting data that will be presented at the 21st annual CTOS meeting in Lisbon, Portugal.

The key to inducing durable responses with immunotherapy in multiple myeloma may depend on the effective use of combination strategies, particularly for the use of monoclonal antibodies.

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a recent study of novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in ovarian cancer.

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy (H-RT) is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Puneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.

Patients with low-risk meningioma had a 3-year progression-free survival (PFS) that modestly exceeded expectations after gross total resection followed by observation, results of a cooperative group trial showed.

Ann H. Klopp, MD, PhD, discusses the results of a recent trial comparing standard radiation to intensity-modulated radiation therapy (IMRT) in endometrial and cervical cancer, and what impact these results will have.

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).

Adding a Toll-like receptor 8 agonist (TLR8) to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) failed to improve progression-free survival (PFS).

A streamlined, oncologist-led <em>BRCA</em> testing program showed potential for reducing time and improving acceptance of testing and counseling for patients with ovarian cancer.

In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.

The rate of complete resection at interval debulking in advanced ovarian cancer increased significantly over reference values with the addition of bevacizumab (Avastin) to neoadjuvant to platinum-based chemotherapy.

For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.

Results from a phase II study from Korea demonstrated high rates of tumor local control, overall survival (OS), and grade 1/2 gastrointestinal and hepatic toxicities in patients who received stereotactic body radiotherapy (SBRT) for unresectable hepatocellular carcinoma (HCC) after incomplete transarterial chemoembolization (TACE).

A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity&mdash;including longer survival&mdash;in a small clinical trial of patients with metastatic breast cancer.

Patients with head and neck cancer whose disease is associated with <em>KRAS</em> variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.

Melanie Royce, MD, details recent studies into&nbsp;hormone receptor-positive (HR+) and HER2-advanced breast cancer treatment.

Sara Hurvitz, MD, discusses the results from a preplanned interim analysis in HR+, HER2-negative breast cancer.

Although one patient with recurrent ovarian cancer achieved complete response,&nbsp;the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.

Combined ipilimumab and nivolumab administered pre- and post-surgery reduced the tumor burden in patients with Stage III B/C melanoma, according to first results from the OpACIN trial reported at the ESMO 2016 Annual Congress.&nbsp;

Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1&ndash;positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency (EMA) applications were reported at the 2016 ESMO Congress.

Almost 40% of patients with resected early-stage non&ndash;small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

Findings of a recent preliminary clinical trial showed one-fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7).

The majority of heavily pretreated patients with high-grade ovarian cancer (HGOV) and germline or somatic <em>BRCA</em> mutations showed a durable response to rucaparib, according to findings from an analysis of two phase II trials.